Merck & Co Inc (MRK)

62.34
0.13 0.21
NYSE : Health Care
Prev Close 62.21
Open 62.33
Day Low/High 62.10 / 62.68
52 Wk Low/High 47.97 / 65.46
Volume 9.97M
Avg Volume 11.23M
Exchange NYSE
Shares Outstanding 2.76B
Market Cap 171.52B
EPS 1.60
P/E Ratio 31.74
Div & Yield 1.88 (3.00%)

Latest News

Merck Is a 'Risk Worth Taking' in Spite of Trump Comments, Top Trader Claims

Merck Is a 'Risk Worth Taking' in Spite of Trump Comments, Top Trader Claims

Merck has 'all the momentum right now,' Lebenthal Asset Management CEO Jim Lebenthal said.

Jim Cramer -- We Can't Stifle Innovation in Health Care

Jim Cramer -- We Can't Stifle Innovation in Health Care

Rising drugs prices are a concern to Donald Trump but we can't let development of 'wonder drugs' slow in the health care sector, Cramer said.

Why You Should Watch These 6 Stocks Rising on Unusual Volume

Why You Should Watch These 6 Stocks Rising on Unusual Volume

Unusual volume flow could mean a spike in volatility. Here's a technical look at how to trade six stocks, including Smucker's and Merck.

Analysts' Actions -- Bank of America, Merck, Morgan Stanley, Valero and More

Analysts' Actions -- Bank of America, Merck, Morgan Stanley, Valero and More

Here are Thursday's top research calls, including upgrades for Bank of America, Merck and Morgan Stanley, and a downgrade for Valero.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session

Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session

Like President-elect Donald Trump's first press conference since securing victory, Wall Street's trading on Wednesday was unpredictable.

Stocks Back to Gains in Unsettled Trade After Trump News Conference

Stocks Back to Gains in Unsettled Trade After Trump News Conference

The Nasdaq falls from records in a volatile session following President-elect Donald Trump's first press conference since winning the election.

Cramer: Trump Doesn't Seem to Care About the Trump Rally

Cramer: Trump Doesn't Seem to Care About the Trump Rally

He's never really been a stock market guy anyway.

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

U.S. stocks fluctuated Wednesday after President-elect Trump targets the biotech industry in his first press conference since July.

For Merck, Keytruda Is 'Extraordinarily Positive' : More Squawk From Jim Cramer

For Merck, Keytruda Is 'Extraordinarily Positive' : More Squawk From Jim Cramer

Merck's lung cancer treatment will get a speedy review by the FDA, but it 'knows better than to go out and give false hope,' TheStreet's Jim Cramer said.

Why Rite Aid, Ford, Merck Are Wednesday's Most Active Movers

Why Rite Aid, Ford, Merck Are Wednesday's Most Active Movers

Here's a technical look on how to trade seven of today's most active stocks.

Stocks Mostly Lower as Trump Targets Pharma Industry

Stocks Mostly Lower as Trump Targets Pharma Industry

The Nasdaq takes a turn lower on Wednesday as President-elect Donald Trump targets the biotech and pharmaceutical industry in a press conference.

Cramer: What Happened to the Pajama Traders?

Cramer: What Happened to the Pajama Traders?

The terror that the futures struck, rightly or wrongly, has disappeared.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

These four Dow components (and eight others I'm watching) are nowhere near record highs.

Merck Cancer Drug Test Sends Incyte Shares Higher

Merck Cancer Drug Test Sends Incyte Shares Higher

The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Technology Rules as Only S&P Sector Hitting a New High

Technology Rules as Only S&P Sector Hitting a New High

Of the 11 S&P 500 sectors, technology leads followed by gain from health care and consumer discretionary stocks. Here's how you trade these sectors using exchange-traded funds.

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of...

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

You have to think that if these stocks were so high once, then it's likely they will be again.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Jim Cramer ponders how too few stocks are doing too much in the Dow's race to 20,000 and how there isn't enough GANG to go with all the FANG.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

Merck To Participate At The 35th Annual J.P. Morgan Healthcare Conference

Merck To Participate At The 35th Annual J.P. Morgan Healthcare Conference

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

'Mad Money' Lightning Round: AMD Is Back and Can Still Go Higher

'Mad Money' Lightning Round: AMD Is Back and Can Still Go Higher

Jim Cramer says Advanced Micro Devices is doing better than people think. And, he's bullish on Merck, Kimberly-Clark and Costco.